Phase 2 Lung Cancer Trial, Recruiting (NCT06490081)

Phase 2 Lung Cancer Trial, Recruiting NCT06490081 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06490081 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with limited-stage small cell lung cancer, confirmed by a tissue sample test
You are able to carry out some or all of your normal daily activities (a measure of general health and activity level scored 0–2)
Your organs (such as liver, kidneys, and bone marrow) are working well, and you have not needed blood transfusions, certain growth-stimulating injections, or albumin/blood product transfusions in the past 14 days
You are suitable to be treated with the drug Trilaciclib combined with the chemotherapy drugs etoposide and either cisplatin or carboplatin
You are able to understand and sign a consent form agreeing to take part in the study

Who may not be able to join:

You have cancer that has spread to the brain and is causing symptoms that need radiation treatment or steroid medications
You currently have an active infection that requires treatment throughout your whole body (such as antibiotics or antiviral medication)
You have an active autoimmune disease (where your immune system attacks your own body), or have had one in the past
You have been diagnosed with another type of cancer at the same time
You have another serious or unstable medical condition that, in the doctor's opinion, could affect your safety, interfere with the study, or make the results unreliable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06490081

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase: Phase 2

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT06490081

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with limited-stage small cell lung cancer, confirmed by a tissue sample test
You are able to carry out some or all of your normal daily activities (a measure of general health and activity level scored 0–2)
Your organs (such as liver, kidneys, and bone marrow) are working well, and you have not needed blood transfusions, certain growth-stimulating injections, or albumin/blood product transfusions in the past 14 days
You are suitable to be treated with the drug Trilaciclib combined with the chemotherapy drugs etoposide and either cisplatin or carboplatin
You are able to understand and sign a consent form agreeing to take part in the study

Who may not be able to join:

You have cancer that has spread to the brain and is causing symptoms that need radiation treatment or steroid medications
You currently have an active infection that requires treatment throughout your whole body (such as antibiotics or antiviral medication)
You have an active autoimmune disease (where your immune system attacks your own body), or have had one in the past
You have been diagnosed with another type of cancer at the same time
You have another serious or unstable medical condition that, in the doctor's opinion, could affect your safety, interfere with the study, or make the results unreliable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Registry

ClinicalTrials.gov

Start date

26 June 2024

Est. completion

30 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Occurrence of severe neutropenia; Duration of severe neutropenia; Occurrence of hematological toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov